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Abstract
Preeclampsia is a leading cause of maternal and fetal/neonatal mortality and morbidity worldwide.
The early identification of patients with an increased risk for preeclampsia is therefore one of the
most important goals in obstetrics. The availability of highly sensitive and specific physiologic and
biochemical markers would allow not only the detection of patients at risk but also permit a close
surveillance, an exact diagnosis, timely intervention (e.g. lung maturation), as well as simplified
recruitment for future studies looking at therapeutic medications and additional prospective
markers. Today, several markers may offer the potential to be used, most likely in a combinatory
analysis, as predictors or diagnostic tools. We present here the current knowledge on the biology
of preeclampsia and review several biochemical markers which may be used to monitor
preeclampsia in a future, that, we hope, is not to distant from today.
Background
Preeclampsia occurs in 2–5% of pregnancies in the Occi-
dent, but it complicates up to 10% of pregnancies in the
developing countries, where emergency care is often inad-
equate or lacking. Therefore we are in need of a widely
applicable and affordable test that could permit presymp-
tomatic diagnosis in order to identify and monitor the
patients at risk and thus provide the best prenatal care for
these women and their child. Such a test would also be of
benefit to confirm a confounding clinical diagnosis and
for future studies investigating prophylactic treatments or
temporizing therapies.
To be effective a screening test need to be sufficiently sen-
sitive and specific and must provide an adequate postive
predictive value [1]. Today, several promising markers
have been described, alone or in combination, that might
fulfill these criteria. However, these data came often from
small case studies with selected populations. Therefore,
there is a need for worldwile large scale prospective stud-
ies to confirm the sensitivity and specificity of these prom-
ising markers and assess their utility in different subtypes
of preeclampsia before they could serve in clinically useful
screening tests.
Furthermore, when evaluating new screening strategies,
not only sensitivity, specificity and predictive values
should be taken into account, but also costs, patient's
acceptability and quality control [2]. Thus, the implemen-
tation of clinical tests will require close collaboration
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between the medical institutions, optimally in a world-
wide network, together with the pharmacieutical industry
in order to develop functional and, as best as possible,
affordable tests which could profit to the pregnant women
worldwide.
Preeclampsia
Preeclampsia is a multi-system disorder of pregnancy,
which is characterized by new onset hypertension (systo-
lic and diastolic blood pressure of ≥ 140 and 90 mm Hg,
respectively, on two occasions, at least 6 hours apart) and
proteinuria (protein excretion of ≥ 300 mg in a 24 h urine
collection, or a dipstick of ≥ 2+), that develop after 20
weeks of gestation in previously normotensive women
[3,4]. Dependent on the systemic involvement, several
other symptoms, such as edema, disturbance of hemosta-
sis, renal or liver failure, and the HELLP syndrome (hemo-
lysis, elevated liver enzymes, and low platelet counts) also
complicate the clinical picture. Preeclampsia can have an
early onset (preeclampsia starting before 34 weeks of ges-
tation) or late onset (preeclampsia starting after 34 weeks
of gestation), can show mild or severe symptoms (systolic
blood pressure ≥ 160 mmHg or diastolic blood pressure ≥
110 mmHg, proteinuria >5 g/24 hours, oliguria, neuro-
logical symptoms, other clinical symptoms such as
deranged liver function, thrombocytopenia < 100 000
mm3, HELLP syndrome), and can evolve in eclampsia in
the most severe cases. In addition, it can manifest as a
maternal disorder only, with an appropriate fetal growing,
or it can present itself with a growth restricted fetus (in
utero growth restriction (IUGR)) or sudden fetal distress.
The disorder has a higher incidence among nulliparous
women, in women who conceive with assisted reproduc-
tion techniques, and in women affected by autoimmune
disorders, reflecting the probable influence of an "inexpe-
rienced" or dysregulated maternal immune system in its
emergence [5,6]. On the other hand, women with pre-
existing metabolic, vascular or renal disease are especially
at increased risk for superimposed preeclampsia [7], pos-
sibly due to their elevated sensitivity to the mere normal
physiological changes imposed by pregnancy itself.
Despite extensive clinical trials, up to date, no therapeutic
approaches are available for either treatment or preven-
tion of preeclampsia. Anti-hypertensive drugs, corticoster-
oids for lung maturation or magnesium sulfate to prevent
from eclampsia (RCOG Guideline No. 10(A)) are given to
handle (or prevent the worsening of) the symptoms and
can thus temporize over the short term to allow for safe
delivery with a more mature fetus. However, the maternal
risks must be carefully weighted against the possible fetal
benefits in temporizing management, as the risk of fatal
deterioration of the maternal and/or fetal health condi-
tion is high. Several prophylactic therapies (anti-oxidant
vitamins, calcium or folic acid supplementation, Aspirin)
have so far failed to prove efficacious in the prevention of
preeclampsia in healthy, nulliparous subjects, although
some benefit has been shown in high risk groups (see [8-
12] for a review on the different trials). As a consequence,
the sole, though radical, resolution of preeclampsia is the
removal of the placenta, and in case of prematurity, with
the adverse consequence of delivering a pre-term baby.
Therefore, preeclampsia, with or without IUGR, remains a
major cause of maternal and neonatal mortality and mor-
bidity worldwide.
Placental pathophysiology in preeclampsia
The precise origin of preeclampsia remains elusive, but it
is believed to be likely multifactorial. A certainty is the
central role played by the placenta in its pathology [13-
15]. A long standing hypothesis has been that preeclamp-
sia develops as a consequence of some kind of immune
maladaptation between the mother and the fetus during
the very first weeks of pregnancy, leading to a 2-step dis-
order progression that can be summarized as following: in
a first – asymptomatic – step, local aberrant feto-maternal
immune interactions within the uterine wall lead to
impaired tissue and arterial invasion by trophoblast cells.
This results in failed transformation of the uterine spiral
arteries and subsequently worsened placental perfusion.
Chronic hypoxia or alternate periods of hypoxia/re-oxy-
genation within the intervillous space is expected to trig-
ger tissue oxidative stress and increase placental apoptosis
and necrosis [16,17]. the clinical disorder arises, in a sec-
ond step, when the maternal vascular and immune sys-
tems cannot handle any longer the increased shedding of
placentally-produced debris and the aberrant expression
of pro-inflammatory, anti-angiogenic and angiogenic fac-
tors, leading to a systemic endothelial cell dysfunction
and an exaggerated inflammatory response [3,18,19].
Recently, this hypothesis has been challenged [20]. It was
proposed instead that intrinsic failure in trophoblast dif-
ferentiation at different time points of ontogeny may lead
to either a mild disorder with late-onset appearance, or
IUGR complicated or not with the maternal symptoms.
However, the origin of preeclampsia might not be
restricted to an alteration of trophoblast differentiation,
but may also in some cases depend on an underlying
maternal constitutional factors such as genetic, obesity,
dysfunctional maternal clearance or inflammatory sys-
tems [21].
Potential benefits of biochemical markers in preeclampsia
Regardless of the lack of existing prophylactic and thera-
peutic means against preeclampsia, the search for non-
invasive, blood-borne or urinary biomarkers that could
predict the development or assist in the detection of this
life-threatening pregnancy disorder is still of utmost
importance. The availability of such markers could haveReproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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decisive impact on the medical management of pregnant
women and their child (e.g. refer to a tertiary centre) but
also on the health costs associated with this poor medical
condition. Since many years, different biophysical and
biochemical markers have been investigated, based on
pathophysiological observations that have been noted in
case of preeclampsia, such as placental dysfunction, a gen-
eralized inflammatory response, endothelial dysfunction
and activation of the coagulation system.
- Miss-diagnosis is still an issue in hospital- or community
midwifery care owing to the multiple clinical symptoms
associated with the syndrome [22]. The availability of one
or several reliable biochemical indicators might thus help
to ascertain a clinical diagnosis.
- Biochemical markers might allow the stratification of
preeclamptic patients in different categories according to
symptoms severity and/or pregnancy outcome and thus
improve its clinical management [23].
- Very importantly, biomarkers might ensure a reliable
early disease assessment in asymptomatic pregnant
women, in particular among target groups at increased
risk based on their clinical history (preeclampsia or hyper-
tension in a previous pregnancy) or pre-pregnancy state
(hypertension, obesity, autoimmune disease are examples
of the latter).
On account of the current understanding of the etiology
of this life-threatening pregnancy disorder, a major focus
of research has recently been the identification of placen-
tal factors showing abnormal expression in preeclamptic
placentas and the assessment of their potential use for
non-invasive early prediction or early detection. On the
other hand, it appears that maternally-expressed proteins
may also serve this purpose. We review below a selected
choice of the most promising markers that have been
identified up to now (Table 1), with an emphasis on the
factors which have been the subject of large-scale studies
and for whom the data are not disputed.
Biomarkers
Angiogenic factors
Angiogenesis requires the complex interplay between the
pro-angiogenic factors vascular endothelial growth factor
Table 1: Summary of potential biochemical markers for the prediction (1. trimester, 2. trimester) or the detection (Manifest 
preeclampsia) of preeclampsia in maternal peripheral blood.
Plasma concentrations
Biochemical Marker 1. trimester 2. trimester Manifest
preeclampsia
Reported
combinations
for prediction
Altered levels are also correlated 
with
sflt-1 -- ↑↑ - sEng, PlGF
VEGF
-Ultrasound
--
sEng -- ↑↑ -sflt-1, PlGF
-Ultrasound
-IUGR
-HELLP
-SGA
PlGF ↓↓ ↓ -sEng, sflt-1 -SGA
PP-13 ↓↑ ↑ -Ultrasound -IUGR
-Preterm delivery
P-Selectin ↑↑ ↑ Activin A, sflt-1
Other adhesion molecules
--
Cell-free fetal DNA ↑↑ ↑ -Inhibin-A -IUGR
-polyhydramnios
-trisomy 21
-preterm labour
Cell free DNA -- -- ↑
ADAM12 ↓ -- -- -- -trisomy 21
-trisomy 18
-small for gestational age
PTX3 ↑↑ ↑ -- -IUGR
PAPP-A ↓↓ ↓ -- -birthweight
Visfatin -- ↑↓ ↑↓ -- -type-2 diabetes mellitus
- gestational diabetes mellitus -obesity
-IUGR
Adreno-
medullin
↑↑ ↑ -- -vascular disorders
sflt-1: soluble fms-like tyrosine kinase 1; sEng: soluble Endoglin; PlGF: placental growth factor; PP-13: Placental protein 13; ADAM12: A 
disintegrin and metalloprotease 12; PTX3: Pentraxin 3; PAPP-A: pregnancy-associated plasma protein A; IUGR: Intrauterine growth retardation; 
SGA: Small for gestational age; HELLP: Hemolysis elevated liver enzymes; low plateletsReproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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(VEGF) and placental growth factor (PlGF) with their cog-
nate receptors VEGF receptor-1 (VEGFR-1, which is alter-
natively called fms-like tyrosine kinase (flt)-1) and
VEGFR-2 (for a review on the function of these factors:
[24]). Interestingly, the placenta is a rich source of these
factors [25-28]. In addition to regulating blood vessel
homeostasis, VEGF, PlGF and the flt-1 receptor have been
shown to be key components in regulating trophoblast
cell survival and function [25,29-31].
Placental cells also secrete a soluble isoform of flt-1,
which is generated through alternative splicing of the
messenger RNA and acts as an anti-angiogenic factor by
interacting with, and thereby neutralizing, PlGF and VEGF
[32]. There is strong evidence for the occurrence of higher
placental expression of sflt-1 and repeated findings of ele-
vated circulating levels of sflt-1 and reduced free bioactive
PlGF and VEGF in preeclamptic patients [18,33-37]. It was
thus suggested that a part of this excess of circulatory sflt-
1 may stem from the placenta.
Maternal blood levels of sflt-1 were shown to correlate
with the severity of preeclampsia, whereas, in an opposite
manner, the quantities of bioactive VEGF and PlGF were
further decreased in patients with severe symptoms com-
pared to normal pregnant women or preeclamptic
patients with mild symptoms [18,33,38]. Alterations in
sflt-1 and PlGF are also more pronounced in early onset-
in comparison to late onset preeclampsia [38,39]. How-
ever, it was also shown that increased levels of sflt-1 were
also associated with IUGR [40].
Remarkably, when introduced into pregnant rats, exoge-
nous sflt-1 triggers hypertension and proteinuria, symp-
toms akin to those in preeclampsia [18]. Besides,
condition medium of villous explants from preeclamptic
placentas impaired vessel formation in vitro, which could
be restored by prior immuno-depletion of sflt-1 from the
conditioned medium [41]. It has therefore been proposed
that the maternal endothelial dysfunction in preeclamp-
sia was caused by the imbalance of the levels of circulatory
angiogenic factors. Aberrant plasma or serum levels of sflt-
1, VEGF and PlGF can indeed be measured prior the onset
of the symptoms [42-47]. Increased amounts of sflt-1 are
apparent in second trimester-, but not first trimester
blood, in women destined to develop preeclampsia,
whereas PlGF and VEGF levels already show alterations at
the end of the first trimester of pregnancy in these
patients. Three longitudinal studies comparing normo-
tensive pregnancies and pregnancies with preeclampsia as
an end-point, characterized the circulatory expression
profile of these angiogenic factors [42,43,48]. In normo-
tensive pregnancies, sflt-1 levels remain relatively stable
until the last 2 months of gestation when they steadily
increase. This increase is much more pronounced in preg-
nancies ending with preeclampsia and can discriminate
this condition beginning approximately 5 to 8 weeks
before the symptoms arise, in particular in cases with pre-
term (< 37 weeks) symptoms. In contrary to sflt-1, the lev-
els of circulatory PlGF increase gradually and peak at mid
gestation before declining again in uneventful pregnan-
cies. PlGF concentration profile follows a similar pattern
in women who later developed preeclampsia, however
with decreased amplitude. PlGF concentrations are
already significantly reduced at the end of the first trimes-
ter and remain lower throughout pregnancy. Yet, the dif-
ference in circulatory PlGF between normotensive
pregnancies and those affected by preeclampsia is the
highest within weeks of the onset of the clinical symp-
toms. As with sflt-1, the pre-symptomatic levels of circula-
tory PlGF seemed to correlate with the severity or time of
onset of preeclampsia [49]. Urinary PlGF is likewise lower
in preeclamptic patients before and at the time of symp-
toms [50,51].
According to some studies, the presymptomatic altera-
tions in sflt-1 levels appeared to be specific for preeclamp-
sia as no changes are detected in women who later deliver
SGA neonate or whose pregnancies are complicated by
IUGR, compared to women with normal pregnancy out-
come [48,52]. However, others found that in a selected
group of patients with abnormal uterine perfusion, simi-
lar alterations in sflt-1 and PlGF levels could be detected
during the second trimester in cases with subsequent
IUGR [53]. Nevertheless, owing to the evolving unbalance
of angiogenic factors after 25 weeks of gestation in women
with subsequent preeclampsia, the ratio sflt-1/PlGF has
been advocated to be a reliable marker of overall preec-
lampsia risk. As a matter of fact, soluble flt-1 and PlGF
have been launched by Roche as a screening test for preec-
lampsia in the second trimester in Europe and is expected
to be submitted to the FDA soon.
It has recently been reported that patients with preeclamp-
sia have lower plasma concentrations of soluble VEGF-R2
[54]. However, this biomarker may not be specific for
preeclampsia as an equivalent decrease was observed in
patients with SGA babies in the absence of preeclampsia.
Soluble Endoglin
Endoglin (Eng) is a co-receptor for transforming growth
factor (TGF)-β1 and TGF-β3 that is highly expressed on
cellular membranes of the vascular endothelium and on
the syncytiotrophoblast [55,56]. It functions as a modula-
tor of TGF-β signaling and is involved in angiogenesis and
the regulation of the vascular tone [57,58]. A circulatory
form of endoglin, which consists of the extra cellular part
of the molecule that may be produced through the proteo-
cleavage of the placental membrane-bound form, has
been identified in normal pregnancy and in preeclampsiaReproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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[59]. In vitro, sEng acts as a negative regulator of angio-
genesis by competitive interaction with TGF-β, thereby
impairing capillary formation by endothelial cells. Fur-
thermore, it induces high arterial pressure and vascular
permeability in pregnant rats in which the protein was
over-expressed. Very interestingly, the combined intro-
duction of sEng and sflt-1 in the pregnant animals
induced renal, placental and hepatic changes reminiscent
of the HELLP syndrome [59].
Soluble Eng is present in substantial excess in preeclamp-
tic patients compared to normotensive controls, and its
concentrations appear to increase with the severity of the
symptoms and are the highest in preeclampsia compli-
cated by the HELLP symptom [40,59,60]. Pregnancies
with IUGR without the maternal syndrome may also be
characterized by elevated levels of sEng, suggesting that
this factor is not specific for preeclampsia, but may be a
marker for clinical conditions associated with an underly-
ing placental pathology [40,60]. However, these results
remain conflicting as others demonstrated no association
between IUGR and the levels of sEng [60]. Moreover, a
pilot study has suggested that sEng may prove useful in
differentiating preeclampsia from other hypertensive dis-
eases of pregnancy, such as gestational- or chronic hyper-
tension [61]. Large scale studies will be needed in order to
clarify these important issues.
Like sflt-1, sEng concentrations raise during the last 2
months of normal pregnancy. In pregnancies ending with
preeclampsia, this increase occurs earlier and is steeper
[48,62-65]. The distinction becomes significant starting
9–11 weeks before the clinical symptoms, for both early
and late onset preeclampsia, but is more prominent for
preterm preeclampsia or in women in whom preeclamp-
sia is complicated with SGA. Altered levels of this factor
throughout gestation are also associated with SGA preg-
nancies without the maternal symptoms [48,66]. Thus, a
specific prediction can not be achieved with this analyte
alone.
Several longitudinal case-control studies have therefore
evaluated the potential of sEng in combination with the
pro- and anti-angiogenic factors PlGF and sflt-1 for the
prediction of preeclampsia [48,62,63]. The studies
reported that the pattern of changes in the ratio of differ-
ent combinations of these factors (PlGF/sEng; (sflt-
1+sEng)/PlGF; etc), collected at 13 weeks and around 20
weeks, was more informative than the individual biomar-
kers at single time-point screening. One study suggested
that a rigorous monitoring of the sequential changes in
the profile of these three biomarkers between the first and
the second trimesters permits sensitive and specific risk
assessment [66]. A change in PlGF/sEng ratio that was
below the median slope for controls conferred an odds
ratio of 7.68 for the development of pre-term preeclamp-
sia, and 2.46 for the development of term preeclampsia,
and discriminated SGA pregnancies from preeclampsia.
Further studies with large number of patients will be
required to confirm these very promising preliminary
results and assess the utility of analyzing these biomarkers
in the clinical routine.
P-Selectin
P-selectin is a member of the selectin family of cell surface
adhesion molecules. It is expressed by platelets and
endothelial cells upon activation and plays crucial roles in
inflammatory reactions by supporting the recruitment
and activation of circulating leucocytes, and in coagula-
tion through the generation of leukocyte-derived "blood-
borne" tissue factor [67,68]. P-selectin is rapidly shed
from the cellular membrane of activated platelets and this
release is suggested to contribute to most of the soluble
isoform of the molecule that is found in the plasma [69].
Preeclampsia is associated with extensive platelet activa-
tion [70-72]. P-selectin-exposing micro particles with pro-
coagulant activity, released from activated platelets, have
been detected in the peripheral blood of preeclamptic
women [73,74]. In addition, soluble P-selectin has been
repeatedly, though not constantly, observed in higher
amounts in serum or plasma of patients with this disorder
[75-78].
Interestingly, it has recently been shown that alterations
in the levels of soluble P-selectin before 20 weeks of ges-
tation antedate the symptoms [79-81]. This early up-regu-
lation of soluble P-selectin has been suggested to reflect
the early but still asymptomatic disturbances of the mater-
nal vascular system. In one of these studies, P-selectin was
identified as the marker with the highest discriminatory
ability among three biomolecules evaluated between ges-
tational weeks 11 to 15 [79]. However, the combination
of P-selectin with the two other markers, namely Activin A
and VEGFR, showed a detection rate of only 59% (with a
false-positive rate of 5%), which is not sufficient for a pos-
sible routine clinical implementation as a screening test.
Cell-free fetal DNA
Since its detection in maternal plasma many approaches
have been tested to use cell free fetal DNA for non-inva-
sive diagnostic approaches. These include qualitative
analyses like fetal sex analysis [82], determination of the
fetal Rhesus status [83,84] or the analysis of fetal point
mutations [85] as well as the quantitative analysis as an
indicator for several fetal anomalies, e.g. fetal growth
restriction [86], polyhydramnios [87], trisomy [88-90] or
preterm labor [91]. The value of cffDNA in maternal
plasma as an indicator for preeclampsia has first been
reported by Lo et al. in a small scale study in the plasmaReproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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of 20 preeclamptic women and 20 gestational age
matched controls in the third trimester, where cffDNA
was increased approximately 5-fold in women with preec-
lampsia [92]. The same effect was observed in the second
trimester in a study by Zhong et al. in 10 preeclamptic
women and 40 controls [93]. The so far biggest study in
that field was conducted by Levine et al. with 120 preec-
lamptic women and 120 controls: A two- to five-fold
increase of cffDNA levels was monitored starting from
week 17 until three weeks before the onset of preeclamp-
sia [94]. As the amount of fetal DNA is routinely deter-
mined by quantifying Y-chromosome specific sequences,
e.g. SRY (sex determining region Y) and DYS [95], alterna-
tive approaches have been tested to overcome this limita-
tion: An increase of total cell free DNA was observed in
women with preeclampsia at term [96-98] and before the
onset of preeclampsia [98]. Furthermore, approaches to
analyze cffDNA independent from fetal sex, using epige-
netic differences between maternal and fetal DNA have
been developed, e.g. the use of the maspin gene, which is
hypomethylated in fetal tissue [99] or the hypermethyl-
ated fetal promoter sequence of RASSF1A [100]. Although
these approaches are promising, only one study quantify-
ing cffDNA with the RASFF1A approach in 10 women
with preeclampsia and 20 controls has been published
[101]. cffDNA has shown some predictive value for the
prediction of preeclampsia between 20–25 weeks of ges-
tation, however, higher sensitivities and specificities can
be obtained by combining several markers as has been
shown in a nested case-control study for cell free DNA
combined with Inhibin A in the second (n = 15 at risk for
PE), n = 68 controls) and third trimester (n = 34 preec-
lampsia, n = 44 controls) [102]. Currently, several multi-
center studies are being performed to confirm the
predictive value of cffDNA to predict and monitor preec-
lampsia in combination with other potential markers, e.g.
P-selectin, PAPP-A, PP-13, sflt-1, sEng, PlGF).
ADAM12
ADAM12 (a disintegrin  and  metalloprotease 12) is a
membrane bound zinc dependant protease and belongs
to the ADAM protein family, a group of proteins involved
in cell-cell and cell-matrix interactions in fertilization,
muscle development and neurogenesis [103-105]. For
this gene, two alternatively spliced transcripts are known,
a short secreted form and a long membrane-bound form
[106]. The plasma concentration of ADAM12 has been
found to be altered in several pregnancy related disorders.
Several studies have demonstrated that the plasma level of
ADAM12 is decreased in women carrying a fetus with tri-
somy 21 and trisomy 18 [107-110]. It has also been
shown that the ADAM12 concentration is decreased in
women with other aneuploidies and in women with low
for gestational age birth weights [111]. The first connec-
tion of ADAM12 serum levels to preeclampsia was dem-
onstrated by Laigaard et al. in a study with 160 women
with preeclampsia and 324 healthy controls in the first tri-
mester [112]. The serum concentration of ADAM12 was
significantly decreased in women that later developed
preeclampsia. These results were confirmed by Spencer et
al. in a study with two groups (1. n = 64 PE, n = 240 con-
trols, 2: n = 24 cases, n = 144 controls) [113]. However
another study failed to confirm these promising results
but concluded that measurement of ADAM12 does not
provide useful prediction of SGA, preeclampsia, or spon-
taneous preterm delivery [114].
PP-13
Placental protein 13 (PP-13, galectin-13) was first isolated
in 1983 by Bohn et al. [115,116]. It is a relatively small
protein with 139 amino acids (16,118 kDa) which is
highly homologous (69%) to the human eosinophil
Charcot-Leyden Crystal protein, a phospholipase that
belongs to the beta-galactoside binding S-type animal lec-
tin super family. The homodimer which is linked by
disulfide bonds probably has special haemostatic and
immunobiological functions at the feto-maternal inter-
face or a developmental role in the placenta [117]. The
600 bp mRNA transcript is only detectable in placental tis-
sue but not in any other fetal or adult tissue
[115,116,118,119]. The serum levels of PP-13 slowly
increase during a normal pregnancy but abnormally low
levels of PP-13 were detected in first trimester serum sam-
ples of women subsequently developing fetal growth
restriction and preeclampsia, in particular cases with early
onset [120-124]. Elevated serum concentrations of PP-13
have been found in the second and third trimester in
women with preeclampsia, IUGR and in preterm delivery
[123]. For this study 514 controls, 69 cases with preec-
lampsia, 69 cases with IUGR, 52 cases with preterm deliv-
ery and 24 cases with preeclampsia developing before 34
weeks of gestation have been included. Another study
concluded that first-trimester serum levels of PP-13 may
serve as a suitable marker for preterm preeclampsia but
are weak for the prediction of severe preeclampsia and
ineffective for mild preeclampsia at term [125].
Here again the combination of several diagnostic tools
results in improved predictive power as was shown by
combined measuring of first trimester serum PP-13 levels
and median uterine artery pulsatility index by ultrasound.
This combination achieved a detection rate for preeclamp-
sia of 90% with a false positive rate of 6% [126]. However,
this combination of serum PP-13 levels and uterine artery
pulsatility index loses its predictive power when late sec-
ond trimester (22–24 weeks of gestation) serum is ana-
lyzed [127]. Currently a commercial PP-13 test kit is
developed for the first trimester screening for preeclamp-Reproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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sia by Diagnostic Technologies, Haifa. The test has already
been approved in Europe and approval in the United
States is expected in the near future.
PTX3
Pentraxin 3 (PTX3, tumor necrosis factor stimulated gene-
14 [128]) belongs to the same family as C-reactive protein
(CRP) or serum amyloid P component (SAP) and consists
of 381 amino acids. The C-terminus is highly homolo-
gous to SAP and CRP whereas the N-terminus doesn't
show any homology to other proteins. The according gene
is organized into three exons [129] and is extremely evo-
lutionarily conserved from horseshoe crab to human
[130]. Responding to proinflammatory stimuli CRP, SAP
and PTX3 are produced by various tissues. It is also
expressed in tissues undergoing cell death. PTX3 then
interacts with several growth factors, extra cellular matrix
components and certain pathogens but is also involved in
the activation of the complement system [131] and facili-
tates pathogen recognition by phagocytes [132]. During
pregnancy, PTX3 is increasingly expressed in amniotic epi-
thelium, chorionic mesoderm, trophoblast terminal villi,
and perivascular stroma of placentae [132]. Cetin et al.
and Rovere-Querini et al. showed that in case of a future
preeclampsia and IUGR the PTX3 plasma levels are even
more increased in all three trimesters [133,134]. So far no
studies that combine PTX3 with other potential markers
have been performed.
PAPP-A
PAPP-A (pregnancy-associated plasma protein A, pap-
palysin 1, insulin-like growth factor binding protein-4
protease, EC 3.4.24.79) is a disulfide bond linked
homodimeric peptidase of 1628 amino acids and a mass
of 400 kDa [135]. It can be detected during pregnancy in
maternal circulation mainly as a complex with the pro-
form of the eosinophil major basic protein, an inhibitor
of PAPP-A [136,137]. Although the reaction products are
not identified yet, insulin-like growth factor binding pro-
teins are substrates for the hydrolytic activity of PAPP-A
[138]. PAPP-A is supposedly involved in local prolifera-
tive processes, for example bone remodeling [139,140]. In
the recent years decreased plasma levels of PAPP-A have
been reported in all trimesters in women with preeclamp-
sia [141-150]. Furthermore, a correlation between birth
weight and maternal PAPP-A plasma levels have been
reported [151].
Recent candidates
Visfatin
Visfatin (nicotinamide phosphoribosyltransferase
(Nampt) enzyme, EC 2.4.2.12) is an adipokine secreted
by adipose tissue and involved in the biosynthesis of nico-
tinamide adenine dinucleotide as it catalyzes the conden-
sation of nicotinamide with 5-phosphoribosyl-1-
pyrophosphate to yield nicotinamide mononucleotide
[152,153]. Several studies have shown that this protein
shows altered plasma levels in different disorders, e.g.
type-2 diabetes mellitus [154], obesity [155], fetal growth
retardation [156] and gestational diabetes mellitus [157].
A recent cross sectional study by Hu et al. with 27 preec-
lampsia cases, 28 pregnant women in the third trimester
and 28 non-pregnant women demonstrated that the
maternal plasma visfatin levels were significantly
decreased in women with mild preeclampsia and even
more decreased in women with severe preeclampsia
[158]. However, the exact opposite was reported by
Fasshauer et al. [159], indicating that further, larger stud-
ies are necessary to evaluate the potential of Visfatin as a
marker for preeclampsia.
Adrenomedullin
Adrenomedullin is a peptide consisting of 52 amino acids
that exhibits a long lasting hypotensive effect and was first
isolated from pheochromocytoma by Kitamura et al. in
1993 [160]. It is expressed in all organs but predomi-
nantly in vascular endothelial cells and vascular smooth
muscle cells where it regulates circulation and endothelial
permeability [161,162]. The plasma level of adrenom-
edullin is elevated in several disorders, mostly in those
resulting from pathologic processes in vasculature [163].
A medium scale study with 90 women (each 15 normo-
tensive women in the first, second and third trimester, 15
women with preeclampsia between 25–38 weeks of gesta-
tion, 15 normotensive non-pregnant women and 15
hypertensive non-pregnant women) by Senna et al.
showed that the plasma adrenomedullin levels increase
during normal pregnancies. In preeclampsia the AM
plasma levels are higher compared to normal pregnancies
[164]. These results agree with the finding that elevated
AM mRNA levels were found in placental tissue [165]. As
AM acts as vasodilator it makes sense to assume that
increased AM levels are increased to act against the preec-
lamptic hypertension.
Auto antibodies against the angiotensin II type 1 (AT1) 
receptor
This is an old actor whose role in the pathogenesis of
preeclampsia is currently being reevaluated. There is long
time evidence for a role for the renin-angiotensin system
in pregnancy. Exactly a decade ago, it was discovered that
patients with preeclampsia develop agonistic autoanti-
bodies against the second extracellular loop of the AT1
receptor [166]. Several in vitro studies confirmed that
these antibodies can induce a profusion of responses
related to hypertensive disorder in vascular cells and
reduce the migration of trophoblast cells (reviewed in
[167]). However, they are not specific to preeclampsia but
rather mark pregnancies with abnormal uterine artery
Doppler flow, such that they are also found in the circula-Reproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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tion of normotensive women with IUGR [168]. Further-
more, they are present in recipients of unsuccessful kidney
allografts who develop malignant hypertension [169]. At
the time, these data suggested that the AT1 autoantibodies
might be a mere secondary response to a hypoxic vascular
insult. However, a recent study demonstrated a link
between these autoantibodies and the overproduction of
sflt-1 in human trophoblast cells or placental explants
[170], raising a new interest for these molecules. Recently,
a small prospective, nested, case control study has sug-
gested that AT1 autoantibodies were common in patients
with preeclampsia and, although sflt-1 was superior for
early-onset preeclampsia, the AT1 autoantibodies may
represent a better marker for preeclampsia developing at
term [171]. Nevertheless, several questions remain to be
answered before the AT1 autoantibodies could be used in
a diagnosis strategy. First, no data exist as to the presence
of these molecules before the pregnancy or prior the
symptoms develop. Second, the detection still relies on a
cumbersome bioassay, which prevents the initiation of
large scale studies.
Doppler ultrasonography of the uterine arteries
The inadequate placental perfusion has lead to the use of
Doppler ultrasonography to assess the velocity of the
blood flow in the uterine arteries. A persistence of an early
diastolic notch after 24 weeks of gestation or abnormal
flow velocity ratio's has been associated with an inade-
quate trophoblast invasion. Pregnancies associated with
an abnormal uterine Doppler after 24 weeks of gestation
(high pulsatility index and/or presence of an early diasto-
lic notch) are associated with a more than six fold increase
in the rate of preeclampsia [172].
Among high-risk patients with a previous preeclampsia,
doppler ultrasound of the uterine arteries has an excellent
negative predictive value, thus it is an important tool in
patient management and care which is of paramount ben-
efit for patients with PE in a previous pregnancy. However
effort must be made so that this sophisticated technology
becomes available in centers throughout underdeveloped
countries.
A recently published systematic review assessed the use of
Doppler ultrasonography in case of preeclampsia [173]. A
total of 74 studies (69 cohort studies, 3 randomized con-
trolled trials and 2 case-control studies with a total of
79'547 patients, of whom 2498 developed preeclampsia,
were included. The authors showed that Doppler ultra-
sonography of the uterine arteries were less accurate in the
first trimester, than in the second trimester. The combined
data showed that the pulsatility index, alone or in combi-
nation with a persistent notching after 24 weeks of gesta-
tion is the most predictive parameter of Doppler
ultrasonography to predict preeclampsia. This parameter
may be used, especially in combination with other
biomarkers.
Current data do not support the use of Doppler ultra-
sonography for routine screening of patients for preec-
lampsia [174]. However several studies show that the
combination of the measurement of uterine perfusion in
the second trimester and analysis of angiogenic markers
have a high detection rate, especially for early onset preec-
lampsia [53,65,175].
Identification of novel biomarkers
Although a panel of promising biomarkers already exists,
a lot of effort is made to find novel candidates that bear a
greater potential to identify women at risk for preeclamp-
sia, in order to provide the best possible care for these
mothers and children. Several approaches for the identifi-
cation of novel potential biomarkers can be applied.
Microarrays offer the possibility to rapidly screen the pla-
cental transcriptome for up- and down-regulated tran-
scripts in preeclamptic samples compared to healthy
controls hoping that the resulting proteins are excreted
and detectable in maternal plasma. Comparative tran-
scription analyses have been performed to some extent by
several groups [17,176-183], although those groups were
studying the molecular mechanisms of preeclampsia
rather than potential biomarkers. Recently, the microarray
based screening for RNA molecules in maternal circula-
tion that are transcribed in placenta but not maternally
has been reported as a potential source for pregnancy
related biomarkers [184-187], including preeclampsia
[188]. As the microarray technology is evolving rapidly
regarding feature size and the number of available and
well characterized genes, these experiments are performed
continuously.
A more direct approach is to compare the proteome in the
maternal circulation as transcriptome and proteome do
not comply with each other. To cope with the complexity
of human plasma, high throughput methods need to be
employed. The classic approach is comparative 2D-gele-
lectrophoresis of albumin depleted plasma and subse-
quent mass spectrometric analysis of the remaining
proteins that show different quantities [189-191]. This
approach is currently being replaced by a mass spectro-
metric technique based on the iTRAQ® reagent by Applied
Biosystems [192]. Up to eight conditions can be simulta-
neously compared by labeling them with defined mass-
tags. After fragmentation, mass analysis, identification
and quantification the mass-tags allow the allocation of
the proteins to each sample-pool. Therefore, this tech-
nique allows a global quantitative comparison of complex
body fluids like plasma [192-195].Reproductive Biology and Endocrinology 2009, 7:70 http://www.rbej.com/content/7/1/70
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A new direction of research in the field of complex dis-
eases is metabolomics, which consists in the global anal-
ysis of endogenous and secreted metabolites in a
biological system. The first reports investigating the pla-
cental metabolome under varying oxygen tensions or in
plasma of preeclamptic patients revealed novel redox
biomarkers and suggest that this technology might bring
new insights into placental function [196,197].
However, the different -omics profiling techniques are not
suited for simple, low-cost, and rapid routine clinical
screenings. Their use is primarily for the identification of
novel biomarkers within global analyte groups. The next
step is then to develop straightforward methods specifi-
cally designed for use in a hospital environment.
Conclusion
Despite there exists many different potential markers for
preeclampsia, the reliability of these markers in predicting
preeclampsia has been inconsistent between different
studies. Furthermore, preeclampsia is a multifaceted dis-
order, certain say it is not one but several diseases. There-
fore, there is a need for high quality, large scale multi-
center trials which enroll patients with different risks of
developing the syndrome and throughout multi-ethnical
background, in order to assess the predictive value of dif-
ferent markers and finally propose the best marker combi-
nation for a routine use in clinical settings.
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